TrialHaematologica2018

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Mark Bosch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.